Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol

Chronic Respiratory Disease

Volumn 1, Issue 2, 2004, Pages 63-69

  Smith, B J ^a   Appleton, S L ^a   Veale, A J ^b   Mcelroy, H J ^a   Veljkovic, D ^b   Saccoia, L ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

chronic obstructive pulmonary disease (COPD); eformoterol

Indexed keywords

AUTACOID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL; SALBUTAMOL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RESISTANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; AGED, 80 AND OVER; ALBUTEROL; AUTACOIDS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG RESISTANCE; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES;

EID: 32944462091     PISSN: 14799723     EISSN: None     Source Type: Journal    
DOI: 10.1191/1479972304cd028oa     Document Type: Article

References (33)

1. Cydulka R, McFadden ER Jr, Emerman C, Sivinski L, Pisanelli W, Rimm A. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1997; 156: 1807-1812.
2. Burdon J, Edwards R. The chronic obstructive pulmonary disease strategy. Intern Med J 2002; 32: 64-65.
3. Australian Institute of Health and Welfare (AIHW). Australia's Health 2000: the seventh biennial health report of the AIHW. Canberra, Australia: Commonwealth of Australia, 2000.
4. National Heart Lung and Blood Institute, World Health Organisation. Workshop report: global strategy for the diagnosis, management of prevention of COPD. National Institutes of Health, Bethesda, USA, 2001.
5. Jones D, Peters T. Caring for elderly dependents: effects on the carer's quality of life. Age Aging 1992; 21: 421-428.
6. Appleton S, Poole P, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Sys Rev 2002; 3: CD001104-CD001104.
7. Grove A, Lipworth B, Reid P et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-693.
8. Boyd G, Morice A, Pounsford J, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821.
9. Ulrik C. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750-754.
10. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
11. Mahler D, Donohue J, Barbee R et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
12. Stahl E, Wadbo M, Bengtsson T et al. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. J Drug Assess 2002; 5: 81-94.
13. Rossi A, Kristufek P, Levine B et al. Comparison of the efficacy, tolerability and safety of eformoterol dry powder and oral slow-release theophylline in the treatment of COPD. Chest 2002; 12: 1058-1069.
14. Rutten-van Molken M, Roos B, van Noord J. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical setting. Thorax 1999; 54: 995-1003.
15. Guyatt GH, Berman LB, Townsend M et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.
16. Patel A, Jaeschke R, Guyatt GH, Keller JL, Newhouse MT. Clinical usefulness of n-of-1 randomised controlled trials in patients with nonreversible chronic airflow limitation. Am Rev Respir Dis 1991; 144: 962-964.
17. Redelmeier D, Guyatt G, Goldstein R. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996; 49: 1215-1219.
18. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: S1-S28.
19. Guyatt G, Sackett D, Taylor D, Chong J, Roberts R, Pugsley S. Determining optimal therapy-randomised trials in individual patients. N Eng J Med 1986; 314: 889-892.
20. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S121.
21. Senn S. Cross over trials in clinical research. Chichester, UK: John Wiley and Sons, 1993.
22. Jones B, Kenward MG. Design and analysis of cross-over trials. London, New York: Chapman & Hall, 1989.
23. Siafakis N, Vermiere P, Pride N et al. The optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
24. Cazzola M, Matera M. Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med 1999; 93: 227-229.
25. Cazzola M, Santangelo G, Piccolo A et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103-107.
26. Thomson N, Angus R, Quebec-Fehling E, Brambilla R. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998; 92: 562-567.
27. Jones P. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887.
28. O'Donnell D, Lam M, Webb K. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstruc-tive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565.
29. Aalbers R, Ayres J, Backer V et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19: 936-943.
30. Dewar M, Jamieson A, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med 1999; 93: 342-344.
31. Brand P, Quanjer P, Postma D et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 1992; 47: 429-436.
32. Dompeling E, Van Schayck C, Molema J et al. A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of pre-bronchodilator FEV1. Eur Respir J 1992; 5: 975-981.
33. Anthonisen N, Wright E, Hodgkin J. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14-20.